Cell-Based Assays: Technologies and Global Markets – Yahoo Finance

Report Scope: This report is an update of an earlier report of the same title. This report offers a comprehensive analysis of the global cell-based assays market. Segmentation is based on product, type/application and end user.
New York, July 19, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cell-Based Assays: Technologies and Global Markets” – https://www.reportlinker.com/p01414031/?utm_source=GNW
Based on type/application, the market is segmented as drug discovery for validating drug targets/lead profiling assays, absorption, distribution, metabolism, and excretion (ADME) toxicity assays and basic research.

The regional markets covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

The report provides a detailed overview and analysis of the present and future global market for cell-based assay techniques.The report analyzes in detail currently available cell-based assays and their markets.

Industry growth drivers, restraints and opportunities are also discussed in detail. The report also provides information on competitive landscape, elaborative company profiles and the impact of COVID-19 on the market.

Report Includes:
– 63 tables
– An up-to-date review of the global markets for cell-based assays and related technologies
– Analyses of the global market trends, with historic sales data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
– Highlights of the current and future potential in the market for cell-based assays, and areas of focus to forecast this market into various segments and sub-segments
– Estimation of the actual market size for cell-based assays, revenue forecast, and corresponding market share analysis based on product, type/application, end user and geographic region
– Market assessment of the cell-based assays available and currently being used, new developments, spending trends, and revenue prospects for cell-based assays in the pharmaceutical industry
– Coverage of major issues involved in the research and development (R&D) of more effective cell-based approaches for drug discovery
– In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
– Competitive analysis of the market for cell-based assays and updated information on the mergers, acquisitions, collaborations and recent developments during the 2020-2022 period
– Descriptive company profiles of the leading global players, including Becton, Dickinson & Company, Charles River Laboratories, General Electric Healthcare, Merck KGaA and Thermo Fisher Scientific Inc.

Summary:
Cell-based assays are basically experiments used to study, analyze and understand how live cells respond to external factors.These assays are commonly used in drug discovery for validating drug targets.

They are also used in lead profiling, in basic research for understanding cell signaling and function, and for ADME toxicity testing.

It has been observed that pharmaceutical R&D expenses place a significant burden on the healthcare industry because the drug discovery and development entails substantial time and resources to recognize an effective drug that can progress to clinical trial.This long process has a success rate of around 10%-12%, that is only 10% of the drugs get approval after undergoing clinical trials.

So, using cell-based assays will be helpful in the initial step of drug discovery as it will help to screen the compounds.Also, with the advancement of technologies, automated processes are being used for drug screening and development purposes.

Studies have indicated that using methods such as cell-based assays earlier in the drug development cycle will help in eliminating the toxic products and avoid late – stage drug failures and financial losses. Since live cells are used in cell-based assays, they are biologically more relevant and will also help in replacing animal testing.

There is a need to grow product pipelines for companies.The benefits of cell-based assays over in vivo methods have led to their increased use in drug discovery.

In vitro cell-based methods also offer flexibility and cost advantages. In addition, advancements in automation and high-throughput techniques are offering support to this market.

The increasing prevalence of chronic diseases, aging population and increased healthcare expenditure are driving the drug discovery market. There are many diseases that still do not have any approved therapies for cures and depend only on symptomatic management, e.g., amyotrophic lateral sclerosis, cirrhosis, non-alcoholic steatohepatitis, etc. Therefore, cell-based assays will be beneficial for such indications. More research and the increasing prevalence of cancer as well as neurogenerative diseases, such as Alzheimer’s, Parkinson’s disease and other rare indications, will also be contributing factors for the market.

Personalized drug treatment is becoming a reality.In response to the rise in the incidence of a number of diseases and an aging population, the drug discovery industry is developing new and more efficacious drugs based on specific biomarker signatures.

These drugs can be developed and tested to meet specific endpoints with the use of cell-based assays.

The global market for cell-based assays is estimated to be REDACTED in 2020 and is expected to increase to REDACTED by 2027, growing at a CAGR of REDACTED. The cell-based assaymarket is segmented based on application, component, end user, and region.Major players in the market are Thermo Fisher, Danaher, Becton, Dickinson & Company,Merck KGaA, Lonza, PerkinElmer and Promega. The North American region has the highest share of the cell-basedmarket, followed by Europe. This is because of the extensive research and developmental activities taking place in the region, as well as the presence of major players, funding and the increasing prevalence of chronic diseases. All these factors contribute to growth in the market. Based on application, the drug discovery segment has the highest share.
Read the full report: https://www.reportlinker.com/p01414031/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

He’s back at it.
Santosh Rao, head of research at Manhattan Venture Partners, discusses Netflix's earnings results and what it means for the streaming industry going forward.
Yahoo Finance auto reporter Pras Subramanian preview Tesla's second-quarter earnings report, which will be released on Wednesday, July 20.
Follow the real smart money?
Earlier in 2022, in a move that investors didn't appreciate, the company slashed its dividend nearly in half and got kicked out of the elite Dividend Aristocrat group.
U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax — a more traditional kind of vaccine, health officials said Tuesday.
Brian Gardner, Stifel Chief Washington Policy Strategist, sits down with Yahoo Finance Live to discuss the outlook on the Senate's CHIPS Act vote and party sentiments on the bill.
Yahoo Finance Live anchors break down second-quarter earnings for Johnson & Johnson.
Question: I have a comfortable balance in my investment account but have a question about only taking out 4% of my total each year (if necessary). Totaling my federal and state taxes (I live in California), and paying estimates for the next year, plus adding in my broker fees actually totals 4% of my investment balance. Basically I feel like I’m investing to pay taxes and broker fees!
The last few days’ trading have been enough to make our heads spin. Markets have shifted up and down, showing both volatility and a short-term upward trend, a pattern that has investors wondering if this is the start of a sustained run of gains, or just a bear-market rally. Stiffel Chief Equity Strategist Barry Bannister believes that there’s less reason for fear and lays out a strong case for upside. “We forecast the S&P 500 up to 4,200 in 3Q22E and recommend Cyclical Growth groups… for a relie
Investors holding cash and waiting for interest rates to rise before buying bonds may be making a significant mistake. With the Federal Reserve poised to keep interest rates near zero for at least another year, investors should consider purchasing short-term … Continue reading → The post How Much Money Do You Lose by Going With Cash Instead of Bonds? appeared first on SmartAsset Blog.
In this article, we will take a look at the 10 most anticipated earnings to watch on Wednesday. If you want to see some more companies reporting earnings this week, go directly to the 5 Most Anticipated Earnings to Watch on Wednesday. The second-quarter earnings season began last week, with financial stocks being the first […]
Yahoo Finance Live anchors discuss EV maker Nikola failing to win shareholder approval to raise new funds and Paul Pelosi taking stake in Nvidia ahead of key chip manufacturing bill vote.
In this article, we discuss the top 10 multibagger penny stocks to buy in 2022. If you want to skip our discussion on the returns being generated by penny stocks, go directly to the Top 5 Multibagger Penny Stocks to Buy in 2022. Since the start of 2022, the Dow Composite Index, the S&P 500 […]
Occidental (OXY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The two-dose, protein-based shot offers an alternative to gene technology from Moderna and the Pfizer-BioNTech partnership.
ARK said in a statement Tuesday that it will shutter its Transparency ETF at the end of July, just eight months after launching the investment vehicle.
Markets have dropped sharply through the first half of this year, but the news isn’t all bad for investors. The lower share prices we've been seeing offer plenty of opportunities for investors looking to buy the dip, or get in at a discount. The trick is to find them. Jim Cramer, the well-known host of CNBC's 'Mad Money' program, has a few ideas about this situation. In his view, the market turbulence has had the beneficial impact of sorting out the wheat from the chaff and ‘working off the exce
AT&T has struggled and made missteps in the past but we want to be forward looking. The company is scheduled to report earnings before the opening of trading Thursday, so let's check out the charts to see if there can be some capital gains on top of a nice dividend. In the daily bar chart of T, below, we can see that the shares have made a large bottom pattern the past 12 months.
See: We have 25 years until retirement and are saving 25% of our income – are we doing it right? You’ve clearly thought out your cash flow in retirement and the tax consequences of your decisions, as well as your healthcare and housing situation. Advisers typically suggest investing your assets rather aggressively when they’re intended for the long-term, and considering you and your spouse are still young in retirement years, you could have decades to go until your kids actually get that money.

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported